Literature DB >> 11398116

Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.

E D de Kleijn1, R de Groot, A B Lafeber, J Labadie, C J van Limpt, J Visser, G A Berbers, L van Alphen, H C Rümke.   

Abstract

Immunologic memory against meningococci was studied in 177 children (100 children were 10-11 years old and 77 were 5-6 years old) 2.5 years after vaccination with hexavalent meningococcal outer membrane vesicle (OMV) vaccine or hepatitis B (HepB) vaccine. Children were revaccinated with monovalent P1.7(h),4 meningococcal OMV vaccine. Serum bactericidal antibodies (SBAs) were measured before revaccination and after 4-6 weeks. A minimum 4-fold increase in SBAs against serosubtype P1.7(h),4 was detected in 48.5% of the children after hexavalent meningococcal vaccine and in 8.9% after HepB vaccine. Of the initial responders given hexavalent meningococcal vaccine, 78% had > or =4-fold increase in SBAs against strain P1.4. Thus, immunologic memory is present in toddlers and school-aged children previously given 3 hexavalent meningococcal vaccinations. Booster vaccination with monovalent P1.7(h),4 meningococcal OMV vaccine induces a significant increase in SBAs against serosubtype P1.7(h),4 and cross-reactivity against other serosubtypes in the hexavalent vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398116     DOI: 10.1086/320993

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

2.  Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Authors:  Oliver Koeberling; Serena Giuntini; Anja Seubert; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2008-12-24

3.  Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Authors:  Jasper M Bos; Hans C Rümke; Robert Welte; Lodewijk Spanjaard; Loek van Alphen; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; A J Kuipers; C J P van Limpt; W C M Keijzers; A van der Ende; R de Groot; L van Alphen; G P J M van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design.

Authors:  Namrata Misra; Prasanna Kumar Panda; Kavita Shah; Lala Bihari Sukla; Priyanka Chaubey
Journal:  Bioinformation       Date:  2011-06-23

6.  An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Authors:  Peter A van der Ley; Afshin Zariri; Elly van Riet; Dinja Oosterhoff; Corine P Kruiswijk
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.